PATENT CLAIM ANALYSIS

Application Number: 16103830
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "248000"]

Abstract:
Embodiments of a method and/or system can include administering, to a patient with one or more conditions associated with at least one of TMA, TMAO, and/or derivatives thereof, a therapeutically effective amount of a compound for affecting inhibiting one or more CutC enzymes and/or CntA enzymes associated with microorganisms from at least one taxon from a set of microorganism taxa.

Claim (Index 21):
The method of  claim 20 , wherein the enzyme comprises at least one of choline trimethylamine-lyase (CutC) enzyme and Rieske-type oxygenase (CntA) enzyme, and wherein the at least one taxon comprises at least one of Firmicutes (phylum) and Proteobacteria (phylum).

Metadata:
- Claim Count in Document: 7.0
- Percentile: 96.0
- Lexical Diversity: 1.58537
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15610145', '14866398', '15366940', '15605437', '13915299']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7488620326100489
- 35 USC 102 Novelty (BERT): 0.4992555553411831
- Combined Prediction Score: 0.7239013848831624
- Mean Citation Score: 177.96008600000005
- Max Citation Score: 189.16028
- Similarity Product: 118.6543401784134

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test